Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

We sought to investigate the clinical profile(s) associated with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 patients with HCC treated with LEN. Independent factors as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Shimose, Shigeo, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Kuromatsu, Ryoko, Yamaguchi, Taizo, Kawaguchi, Takumi, Tanaka, Masatoshi, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7408786/
https://ncbi.nlm.nih.gov/pubmed/32664489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071867
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados